Top

Published in:

Open Access 01-12-2006 | Review

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Authors: Alexander Tenenbaum, Enrique Z Fisman, Michael Motro, Yehuda Adler

Published in: Cardiovascular Diabetology | Issue 1/2006

Abstract

Lowering of low-density lipoprotein cholesterol with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) is clearly efficacious in the treatment and prevention of coronary artery disease. However, despite increasing use of statins, a significant number of coronary events still occur and many of such events take place in patients presenting with type 2 diabetes and metabolic syndrome. More and more attention is being paid now to combined atherogenic dyslipidemia which typically presents in patients with type 2 diabetes and metabolic syndrome. This mixed dyslipidemia (or "lipid quartet"): hypertriglyceridemia, low high-density lipoprotein cholesterol levels, a preponderance of small, dense low-density lipoprotein particles and an accumulation of cholesterol-rich remnant particles (e.g. high levels of apolipoprotein B) – emerged as the greatest "competitor" of low-density lipoprotein-cholesterol among lipid risk factors for cardiovascular disease. Most recent extensions of the fibrates trials (BIP – Bezafibrate Infarction Prevention study, HHS – Helsinki Heart Study, VAHIT – Veterans Affairs High-density lipoprotein cholesterol Intervention Trial and FIELD – Fenofibrate Intervention and Event Lowering in Diabetes) give further support to the hypothesis that patients with insulin-resistant syndromes such as diabetes and/or metabolic syndrome might be the ones to derive the most benefit from therapy with fibrates. However, different fibrates may have a somewhat different spectrum of effects. Other lipid-modifying strategies included using of niacin, ezetimibe, bile acid sequestrants and cholesteryl ester transfer protein inhibition. In addition, bezafibrate as pan-peroxisome proliferator activated receptor activator has clearly demonstrated beneficial pleiotropic effects related to glucose metabolism and insulin sensitivity. Because fibrates, niacin, ezetimibe and statins each regulate serum lipids by different mechanisms, combination therapy – selected on the basis of their safety and effectiveness – may offer particularly desirable benefits in patients with combined hyperlipidemia as compared with statins monotherapy.

Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA, AHA/ACC; National Heart, Lung and Blood Institute: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006, 113: 2363-2372. 10.1161/CIRCULATIONAHA.106.174516.CrossRefPubMed

Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350: 1495-504. 10.1056/NEJMoa040583.CrossRefPubMed

de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, A to Z Investigators: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004, 292: 1307-1316. 10.1001/jama.292.11.1307.CrossRefPubMed

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005, 352: 1425-1435. 10.1056/NEJMoa050461.CrossRefPubMed

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J: Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005, 294: 2437-2445. 10.1001/jama.294.19.2437.CrossRefPubMed

Fisman EZ, Adler Y, Tenenbaum A: Statins research unfinished saga: desirability versus feasibility. Cardiovasc Diabetol. 2005, 4: 8-10.1186/1475-2840-4-8.PubMedCentralCrossRefPubMed

Christopher CP: The IDEAL cholesterol: lower is better. JAMA. 2005, 294: 2492-2494. 10.1001/jama.294.19.2492.CrossRef

Pitt B: Low-density lipoprotein cholesterol in patients with stable coronary heart disease – is it time to shift our goals?. N Engl J Med. 2005, 352: 1483-1484. 10.1056/NEJMe058052.CrossRefPubMed

Tenenbaum A, Fisman EZ: Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?. Cardiovasc Diabetol. 2004, 3: 10-10.1186/1475-2840-3-10.PubMedCentralCrossRefPubMed

10.

Sacks FM, for the Expert Group on HDL Cholesterol: The role of high-density lipoprotein [HDL] cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. Am J Cardiol. 2002, 90: 139-143. 10.1016/S0002-9149(02)02436-0.CrossRefPubMed

11.

Fruchart JC: Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism. Am J Cardiol. 2001, 88 (12A): 24N-29N. 10.1016/S0002-9149(01)02149-X.CrossRefPubMed

12.

Verges B: Clinical interest of PPARs ligands. Diabetes Metab. 2004, 30: 7-12.CrossRefPubMed

13.

Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987, 317: 1237-1245.CrossRefPubMed

14.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999, 341: 410-418. 10.1056/NEJM199908053410604.CrossRefPubMed

15.

Ericsson CG, Nilsson J, Grip L, Svane B, Hamsten A: Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)). Am J Cardiol. 1997, 8: 1125-1129. 10.1016/S0002-9149(97)00626-7.CrossRef

16.

Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides AN, Mahmood S, Richmond W, Mather H, Sharp P, Feher MD: Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care. 1998, 21: 641-648.CrossRefPubMed

17.

Meade T, Zuhrie R, Cook C, Cooper J: Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ. 2002, 325 (7373): 1139-10.1136/bmj.325.7373.1139.PubMedCentralCrossRefPubMed

18.

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation. 2000, 102: 21-27.

19.

Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet. 2001, 357: 905-910. 10.1016/S0140-6736(00)04209-4.CrossRef

20.

Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S: Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005, 165: 1154-1160. 10.1001/archinte.165.10.1154.CrossRefPubMed

21.

Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992, 85: 37-45.CrossRefPubMed

22.

Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002, 162: 2597-2604. 10.1001/archinte.162.22.2597.CrossRefPubMed

23.

Tenkanen L, Manttari M, Kovanen P, Virkkunen H, Manninen V: Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med. 2006, 166: 743-748. 10.1001/archinte.166.7.743.CrossRefPubMed

24.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366: 1849-1861. 10.1016/S0140-6736(05)67667-2.CrossRefPubMed

25.

Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000, 43: 527-550. 10.1021/jm990554g.CrossRefPubMed

26.

Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 2002, 53: 409-435. 10.1146/annurev.med.53.082901.104018.CrossRefPubMed

27.

Tenenbaum A, Motro M, Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol. 2005, 4: 14-10.1186/1475-2840-4-14.PubMedCentralCrossRefPubMed

28.

Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S: Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med. 2006, 166: 737-741. 10.1001/archinte.166.7.737.CrossRefPubMed

29.

Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S: Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation. 2004, 109: 2197-2202. 10.1161/01.CIR.0000126824.12785.B6.CrossRefPubMed

30.

Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S: Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J. 2005, 26: 2032-2038. 10.1093/eurheartj/ehi310.CrossRefPubMed

31.

Bloomfield HE: The role of fibrates in a statin world. Arch Intern Med. 2006, 166: 715-716. 10.1001/archinte.166.7.715.CrossRefPubMed

32.

Groop LC: Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab. 1999, S1-S7. 10.1046/j.1463-1326.1999.0010s1001.x. Suppl 1

33.

Tenenbaum A, Fisman EZ, Motro M: Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol. 2003, 2: 4-10.1186/1475-2840-2-4.PubMedCentralCrossRefPubMed

34.

Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002, 288: 2709-2716. 10.1001/jama.288.21.2709.CrossRefPubMed

35.

Fruchart JC, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep. 2001, 3: 83-92.CrossRefPubMed

36.

Rovellini A, Sommariva D, Branchi A, Maraffi F, Montalto C, Gandini R, Fasoli A: Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia. Pharmacol Res. 1992, 25: 237-245. 10.1016/S1043-6618(05)80072-6.CrossRefPubMed

37.

Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 2001, 50: 477-480. 10.1053/meta.2001.21028.CrossRefPubMed

38.

Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH: Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med. 2002, 112: 275-280. 10.1016/S0002-9343(01)01123-8.CrossRefPubMed

39.

Jones IR, Swai A, Taylor R, Miller M, Laker MF, Alberti KG: Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM. Diabetes Care. 1990, 13: 855-863.CrossRefPubMed

40.

Despres JP, Lemieux I, Robins SJ: Role of fibric Acid derivatives in the management of risk factors for coronary heart disease. Drugs. 2004, 64: 2177-2198. 10.2165/00003495-200464190-00003.CrossRefPubMed

41.

Jin FY, Kamanna VS, Kashyap ML: Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 1997, 17: 2020-2028.CrossRefPubMed

42.

Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML: Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004, 45: 1835-1845. 10.1194/jlr.M300403-JLR200.CrossRefPubMed

43.

Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S: PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med. 2003, 9: 352-355. 10.1038/nm824.CrossRefPubMed

44.

The Coronary Drug Project Research Group: The Coronary Drug Project: Design, Methods, and Baseline Results. Circulation. 1973, 47: 1-50.CrossRef

45.

Canner PL, Furberg CD, McGovern ME: Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol. 2006, 97: 477-479. 10.1016/j.amjcard.2005.08.070.CrossRefPubMed

46.

Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES: Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005, 45: 185-197. 10.1016/j.jacc.2004.10.031.CrossRefPubMed

47.

Choi BG, Vilahur G, Yadegar D, Viles-Gonzalez JF, Badimon JJ: The role of high-density lipoprotein cholesterol in the prevention and possible treatment of cardiovascular diseases. Curr Mol Med. 2006, 6: 571-587. 10.2174/156652406778018590.CrossRefPubMed

48.

McCormack PL, Keating GM: Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs. 2005, 65: 2719-2740. 10.2165/00003495-200565180-00014.CrossRefPubMed

49.

Garg A, Grundy SM: Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA. 1990, 264: 723-726. 10.1001/jama.264.6.723.CrossRefPubMed

50.

Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, O'Sullivan AJ: Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens. 2000, 14: 567-572. 10.1038/sj.jhh.1001099.CrossRefPubMed

51.

Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LV: Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism. 2003, 52: 699-704. 10.1016/S0026-0495(03)00030-1.CrossRefPubMed

52.

Vega GL, Cater NB, Meguro S, Grundy SM: Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol. 2005, 95: 1309-1313. 10.1016/j.amjcard.2005.01.073.CrossRefPubMed

53.

Shepherd J, Packard CJ, Morgan HG, Third JL, Stewart JM, Lawrie TD: The effects of cholestyramine on high density lipoprotein metabolism. Atherosclerosis. 1979, 33: 433-444. 10.1016/0021-9150(79)90036-4.CrossRefPubMed

54.

The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984, 251: 365-374. 10.1001/jama.251.3.365.CrossRef

55.

Insull W: Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006, 99: 257-273. 10.1097/01.smj.0000208120.73327.db.CrossRefPubMed

56.

Toth PP, Davidson MH: Cholesterol absorption blockade with ezetimibe. Curr Drug Targets Cardiovasc Haematol Disord. 2005, 5: 455-462. 10.2174/156800605774962086.CrossRefPubMed

57.

Sudhop T, Lutjohann D, Kodal A, Igel M, Tribble DL, Shah S, Perevozskaya I, von Bergmann K: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002, 106: 1943-1948. 10.1161/01.CIR.0000034044.95911.DC.CrossRefPubMed

58.

Davis HR, Compton DS, Hoos L, Tetzloff G: Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001, 21: 2032-2038.CrossRefPubMed

59.

Van der Steeg WA, El-Harchaoui K, Kuivenhoven JA, Kastelein JJ: Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?. Curr Drug Targets Cardiovasc Haematol Disord. 2005, 5: 481-488. 10.2174/156800605774961997.CrossRefPubMed

60.

Schaefer EJ, Asztalos BF: Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol. 2006, 17: 394-398. 10.1097/01.mol.0000236364.63840.d8.CrossRefPubMed

61.

Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG, Clark RW, Mancuso JP, Rader DJ: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004, 350: 1505-1515. 10.1056/NEJMoa031766.CrossRefPubMed

62.

de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 2002, 105: 2159-2165. 10.1161/01.CIR.0000015857.31889.7B.CrossRefPubMed

63.

Robins SJ: Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy?. Curr Opin Lipidol. 2003, 14: 575-583. 10.1097/00041433-200312000-00005.CrossRefPubMed

64.

Tenenbaum A, Motro M, Schwammenthal E, Fisman EZ: Macrovascular complications of metabolic syndrome: an early intervention is imperative. Int J Cardiol. 2004, 97: 167-172. 10.1016/j.ijcard.2003.07.033.CrossRefPubMed

65.

Fazio S, Linton MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004, 6: 148-157.CrossRefPubMed

66.

Role of fibrates in reducing coronary risk: a UK Consensus. Curr Med Res Opin. 2004, 20: 241-247. 10.1185/030079903125002892.

67.

Tenenbaum A, Fisman EZ, Motro M: Bezafibrate and simvastatin: different beneficial effects for different therapeutic aims. J Clin Endocrinol Metab. 2004, 89: 1978-10.1210/jc.2003-032038.CrossRefPubMed

68.

Robins SJ, Bloomfield HE: Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol. 2006, 17: 431-439. 10.1097/01.mol.0000236370.27508.9d.PubMed

69.

Verges B: Role for fibrate therapy in diabetes: evidence before FIELD. Curr Opin Lipidol. 2005, 16: 648-651.PubMed

70.

Jokubaitis LA: Fluvastatin in combination with other lipid-lowering agents. Br J Clin Pract. 1996, 28-32. Suppl 77A

71.

Gavish D, Leibovitz E, Shapira I, Rubinstein A: Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med. 2000, 247: 563-569. 10.1046/j.1365-2796.2000.00646.x.CrossRefPubMed

72.

Kyrklund C, Backman JT, Kivisto KT, Neuvonen M, Laitila J, Neuvonen PJ: Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther. 2001, 69: 340-345. 10.1067/mcp.2001.115542.CrossRefPubMed

73.

Beggs PW, Clark DW, Williams SM, Coulter DM: A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP). Br J Clin Pharmacol. 1999, 47: 99-104. 10.1046/j.1365-2125.1999.00846.x.PubMedCentralCrossRefPubMed

74.

Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L: Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am J Cardiol. 2003, 92: 794-797. 10.1016/S0002-9149(03)00885-3.CrossRefPubMed

75.

Farnier M: Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs. 2003, 3: 169-178. 10.2165/00129784-200303030-00003.CrossRefPubMed

76.

Shek A, Ferrill MJ: Statin-fibrate combination therapy. Ann Pharmacother. 2001, 35: 908-917. 10.1345/aph.10315.CrossRefPubMed

77.

Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986, 8: 1245-1255.CrossRefPubMed

78.

Toth PP, Davidson MH: Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother. 2005, 6: 131-139. 10.1517/14656566.6.1.131.CrossRefPubMed

Title: Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
Authors: Alexander Tenenbaum
Enrique Z Fisman
Michael Motro
Yehuda Adler
Publication date: 01-12-2006
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2006
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-5-20

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2006

Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes

Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study

Lipopolysaccharide regulated protein expression is only partly impaired in monocytes from patients with type I diabetes

Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease

Anemia is an independent risk for mortality after acute myocardial infarction in patients with and without diabetes

Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page